BTG2 and pancreatic neoplasm: In this study we have confirmed the involvement of miR-148a-ADAM17, miR-148a-EP300, miR-21-PDCD4 and miR-21-BTG2 interactions in the pancreatic cancer cell with the help of genetically modified pancreatic cancer cellular models (stable overexpression or CRISPR/Cas9 knock-out, respectively).